Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -4 of 4
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
1/31/2008
 
First Published:
10/14/2006
1.
Phase II Study of Tandutinib in Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
MDA-2005-0717
7409, NCI-7409, NCT00390468
Last Modified:
5/24/2008
 
First Published:
12/1/2006
2.
Phase II Study of Tandutinib in Patients Who Have Undergone Cytoreductive Nephrectomy for Metastatic Renal Clear Cell Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
CASE-10805
7401, NCT00408902
3.
Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
Over 18
Pharmaceutical / Industry
01-301
NCT00064584
4.
MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
Pharmaceutical / Industry
C03001
NCT00274248
Select All on One Page
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute